The much anticipated SIRFLOX study has failed to demonstrate a statistically significant increase in progression free survival (PFS; measures the time interval...

Morgans
The much anticipated SIRFLOX study has failed to demonstrate a statistically significant increase in progression free survival (PFS; measures the time interval from trail start to the time when the cancer starts to regrow) for main product SIR-Spheres microspheres combined with chemotherapy compared to chemotherapy alone in secondary liver cancer patients. While the trial did show the product increased PFS in the liver in a statistically significant manner, this is a secondary endpoint of the study which did not translate into any patient benefit. The full trial details to be presented at the American Society of Clinical Oncology (ASCO) meeting held 29 May- 2 June 2015. While we do not expect unfavourable results to negatively impact uptake of the device in its current 'salvage setting', trading levels have optimistically baked-in favourable trial results, with downside of 48-62% as we view fair value in the $15-20 range. Sirtex (SRX, Reduce, Price Target A$15.63) (Source:Derek jellinek) @morgans
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.

2 topics

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Please sign in to comment on this wire.